Eli Lilly's Potential $1B Deal Sends Ventyx Biosciences Stock Soaring 62% in Extended Trading

LiquidityHunter · 2026-01-12T18:56:02+00:00

Ventyx Biosciences saw its stock surge after reports of acquisition talks with Eli Lilly, potentially worth over $1 billion. The market's enthusiasm drove a 28.52% increase during regular trading, with after-hours gains exceeding 90%, reflecting strong investor interest in biotech consolidation.

LiquidityHunter

2026-01-12 18:56:02

Abstract generation in progress

Biotech firm Ventyx Biosciences (VTYX) experienced explosive momentum on Tuesday after reports emerged of ongoing acquisition discussions with pharmaceutical giant Eli Lilly (LLY). According to market sources, the two companies are in substantive negotiations for a transaction that could exceed $1 billion, with an official announcement potentially coming within days.

Stock Performance Reflects Market Enthusiasm

The rally was particularly striking during extended trading hours. During regular market hours on NasdaqGS, VTYX climbed $2.23 to close at $10.05, representing a 28.52% gain by the 4:00 PM EST close. The buying pressure intensified after-hours, with shares reaching $16.34 by 7:59 PM EST—adding another $6.29 per share or 62.59% to the daily move.

Deal Rationale and Strategic Context

Ventyx specializes in developing oral medications targeting inflammatory diseases, a therapeutic area where Eli Lilly has demonstrated strategic interest. The reported valuation of over $1 billion reflects investor confidence in the company’s pipeline and market potential. Sources familiar with the discussions indicate that finalization of terms could arrive imminently, suggesting the Eli Lilly acquisition framework is substantially advanced.

Market Implications

The magnitude of the price action underscores investor appetite for biotech consolidation deals, particularly when established pharma players like Eli Lilly pursue emerging therapeutic solutions. Ventyx shareholders have already benefited significantly, with the combined intraday and after-hours gains exceeding 90% from the open.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.